GLOW: Fixed-duration ibrutinib and venetoclax for first-line CLL

Real world evidence on the use of antibody drug conjugates in peripheral T-cell lymphoma

Palliative Care: Industry and Academia – Tensions and Opportunities

Durvalumab following radiotherapy in patients with unresectable, stage 3 NSCLC ineligible for chemotherapy

OncoAlert and ecancer weekly roundup for March 01 - 06, 2021

Reduced intensity allogeneic HSCT to hypomethylating therapy or best supportive care in older patients with advanced MDS

Haematology updates from SIOG 2020

Guidelines to ensure high quality palliative care

OncoAlert Colloquium Day 4: Gynae-oncology, lymphoma, sarcoma and melanoma

OncoAlert Colloquium Day 2: Lung cancer and SIOG

The present and future agenda of SIOG

SIOG 2020: Prostate task force and geriatric oncology during COVID 19